Department of Physical Medicine & Rehabilitation, Department of Veterans Affairs, Northern California Health Care System, Sacramento, California 95655-1200, USA.
Res Sports Med. 2013;21(2):164-75. doi: 10.1080/15438627.2012.757230.
This study sought to identify runner characteristics or symptoms that could distinguish those finishers developing exercise-associated hyponatremia (EAH) from those not developing EAH in a 161-km ultramarathon. Of 310 finishers, 207 (67%) underwent postrace blood studies. Twelve (6%) finishers had EAH (blood sodium range 131-134 mmol/L). Experience at 161-km ultramarathons was lower (p = 0.01) and blood creatine kinase (CK) concentration was higher (p = 0.04) among those with EAH than those not developing EAH. Blood sodium and CK concentration were negatively correlated (p = 0.0015, r = -0.22). There were no group differences in age, sex, regular running experience, weekly training distance, use of sodium supplements during training, immediately postrace sodium palatability and thirst ratings, body mass change, urination frequency, nonsteroidal anti-inflammatory drugs (NSAIDs) use, and various symptoms experienced during the race. These findings indicate that a clinical suspicion and measurement of blood sodium concentration remain the only viable means for determining when an ultramarathon runner has EAH.
本研究旨在确定跑步者的特征或症状,以区分在 161 公里超级马拉松比赛中发生运动相关性低钠血症 (EAH) 和未发生 EAH 的选手。在 310 名完赛者中,有 207 名(67%)进行了赛后血液检查。12 名(6%)完赛者出现 EAH(血钠范围 131-134mmol/L)。与未发生 EAH 的选手相比,发生 EAH 的选手参加 161 公里超级马拉松比赛的经验较少(p=0.01),血肌酸激酶(CK)浓度较高(p=0.04)。血钠和 CK 浓度呈负相关(p=0.0015,r=-0.22)。两组在年龄、性别、常规跑步经验、每周训练距离、训练期间是否使用钠补充剂、赛后即刻钠适口性和口渴评分、体重变化、排尿频率、非甾体抗炎药(NSAIDs)使用以及比赛期间出现的各种症状方面均无差异。这些发现表明,临床怀疑和血液钠浓度测量仍然是确定超级马拉松选手是否发生 EAH 的唯一可行方法。